cyrilzakka/clinical-trials huggingface dataset:
A Check-list Including Lung Ultrasound for ED Patients With ARF

The aim of the study is to evaluate if a check-list including lung ultrasonography can help to identify the etiology of the acute respiratory failure of patients managed at the emergency room.

Adult patients admitted to the emergency room for acute respiratory failure will be offered the study. The emergency physician will perform a systematic examination using a checklist, including pulmonary embolism prediction scores, structured clinical examination and lung ultrasound, in order to establish a diagnostic hypothesis.

A diagnostic hypothesis will be made after completion of the checklist. The emergency physician can perform additional examinations and treatment after completion of the checklist.

The final diagnosis will be checked by an adjudication committee which will have all the documents established during the emergency room consultation and any hospitalization following this hospitalization.

The main outcome will be the concordance rate between the diagnosis after the check-list and the final diagnosis.


Eligibility Criteria:
Inclusion Criteria:

* Patient with acute respiratory failure table (SpO2 90% in ambient air or need more than 3 L/min of oxygen to have SpO2 \> 92% AND/OR signs of respiratory struggle sign AND/OR respiratory rate control \> 25 cycles/minute AND/OR cyanosis)
* Over 18 years old

Exclusion Criteria:

* Pregnant, Parturising or Breastfeeding Women
* Patient who has already participated in the study in the previous 7 days
RenalGuard System for Prevention of Contrast Induced Nephropathy

The purpose of this study is to determine whether hydration with intravenous saline matched with urine output, using the device RenalGuard is superior to standard hydration with saline to prevent contrast-induced nephropathy.


Eligibility Criteria:
Inclusion Criteria:

* serum creatinine \>1.2mg/dl
* glomerular filtration rate (GFR) \< 60ml/min

Exclusion Criteria:

* acute renal failure
* use of radiological contrast in the latest 7 days
* Current use of N-acetylcysteine or hydration of sodium bicarbonate
* Patients in dialysis
* Emergency procedures
Treatment of Dural Arteriovenous Fistulas With SQUID™ Liquid Embolic Agent

The purpose of this study is assessment of safety, efficacy, and short-term outcome of SQUID™ in the embolization of Dural Arteriovenous Fistula

Traditionally, there are two therapeutic options for the treatment of Dural Arteriovenous Fistula (DAVF): (1) the surgical approach consisting of craniotomy and ligation of the vein and (2) the endovascular approach with embolization of shunting zone. Onyx™ (EVOH (Ethylene Vinyl Alcohol) in solution in an organic solvent, DMSO (Dimethyl Sulfoxide), is the main embolic agent used for the endovascular treatment of DAVF. During the occlusion procedure with Onyx™, residual malformed compartments become gradually less visible on x-ray to the operator, due to the high radiopacity of Onyx™, resulting in a potential risk during treatment. Moreover, viscosity is frequently not as low as required to penetrate the shunt.Thus, development a new embolization system with lower radiopacity and lower viscosity to achieve improved occlusion is needed. SQUID™ is a new liquid embolic agent, with variable radiopacity and viscosity. The purpose of this study is assessment of safety, efficacy, and short-term outcome of SQUID™ in the embolization of DAVFs .

Eligibility Criteria:
Inclusion Criteria:

* Dural Arteriovenous Fistula requiring endovascular treatment with a Lariboisiere score between 3 - 5

  * Intended usage of SQUID™
  * The patient agrees with the clinical data collection and medical file access.

Exclusion Criteria:

* DAVF with a Lariboisiere score \< 3 • Pregnancy
A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of mavacamten in adolescent patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of HCM
* Presence of LVOT obstruction
* Presence of symptoms

Exclusion Criteria:

* Phenocopy diseases resulting in myocardial hypertrophy not related to sarcomere dysfunction
* Evidence of LVEF \<50% in prior 6 months
* Planned escalation in HCM therapy or upcoming intervention (eg, major cardiac surgery, HCM medication dose increase)

Other protocol-defined Inclusion/Exclusion criteria apply.
Use of CtDNA for Monitoring of Stage III Colorectal Cancer

This observational study will evaluate circulating tumor DNA (ctDNA) as a prognostic marker and as a monitor of disease recurrence in stage III colorectal cancer (CRC).

Circulating tumor DNA (ctDNA) are small fragments of nucleic acid that originate from apoptotic or necrotic tumor cell turnover. Characteristic of the malignant process, ctDNA can be assessed in plasma and offers the potential of a sensitive and specific biomarker for prognostic information on disease-free or overall survival, and predictive information on chemotherapy resistance and probability of lack of response to treatment. This study will evaluate ctDNA as a prognostic marker and as a monitor of disease recurrence in stage III colorectal cancer (CRC). We will recruit newly diagnosed stage III CRC patients, determine their tumor mutational profile, and systematically collect high volume (\>10 ml), serial plasma specimens every 3 months for up to 3 years and every 6 months in years 4-5 for ctDNA and concurrent carcinoembryonic antigen (CEA) measurement. Clinical outcome and survival will be tracked. The resulting data will permit assessment of ctDNA as a prognostic marker for disease-free and overall survival and as a monitor of disease recurrence in comparison with CEA.

Eligibility Criteria:
Inclusion Criteria:

* Men and women with CRC Stage III A, B, or C
* Age ≥18 years
* Willingness to provide blood samples for research purposes
* Ability to understand written informed consent document, and written informed consent provided

Exclusion Criteria:

* Blood sampling would compromise patients overall health such as presence of severe anemia
* Unable to give informed consent
Functional Neurological Disorders in Patients Admitted in Stroke Units

Functional neurological disorders are an important subgroup of patients with stroke mimics admitted to stroke unit.Their clinical profile and outcome are poorly known. The goal of this study is to describe the cognitive and behavioral profile of stroke mimics patients, without evidence of neurological disease.


Eligibility Criteria:
Inclusion Criteria:

* Age over 18 years old
* Patients admitted in stroke unit for a neurological deficit, without evidence of neurovascular or othe neurological disease.
* NIHSS ≥ 1 at time of admission
* Informed and consent patient to study
* Health insured

Exclusion Criteria:

* Patient receiving legal protection
* Pregnant or breastfeeding woman
Impact of Bluetooth Haptics Device Distraction on Mechanical Pain Thresholds Induced by PinPrick Stimulators

This is a prospective, crossover study of healthy participants evaluating the mechanical pain threshold for weighted pinprick stimuli.


Eligibility Criteria:
Inclusion Criteria:

* Greater than 18 years of age
* English speaking
* Hearing intact

Exclusion Criteria:

* History of chronic pain or acute pain syndromes
* Currently has nausea
* Has hearing loss
* Is pregnant
* Is currently taking beta blockers, chronotropic heart medications, or opioids or other prescription pain medications
Pharmacogenetics of Ace Inhibitor-Associated Angioedema

The investigators would like to find out if sitagliptin (dipeptidyl peptidase-4 or DPP4 inhibition), a drug to treat diabetes, affects blood vessel relaxation in healthy people receiving enalapril (angiotensin converting enzyme or ACE inhibition), a blood pressure medicine. Understanding how these drugs interact in healthy people will help us learn their potential effects in people who have diabetes.

To test the hypothesis that DPPIV inhibition with sitagliptin potentiates the vasodilator response to substance P in the presence of ACE inhibition with enalaprilat and to BNP and GLP-1 even in the presence of ACE inhibition. The aim promises to provide important new data regarding the mechanism of action of DPPIV inhibitors and interactive effects of these two drug classes used in a growing population of diabetic patients.

Eligibility Criteria:
Inclusion Criteria:

* Age 18 to 65 inclusive
* Men and women
* Black and White Americans
* BMI \<25

For female subjects:

* Postmenopausal status for at least 1 year
* Status post surgical sterilization
* If childbearing potential, utilization of a barrier method of birth control and willingness to undergo blood B-hcg testing prior to drug treatment and on every study day

Exclusion Criteria:

* Smoking
* Diabetes type 1 or 2, as defined by a fasting glucose of 126 mg/dl or greater or the use of anti-diabetic medication
* Hypertension as defined by an untreated seated SBP greater than 140 mmHg an untreated DBP greater than 90 mmHg or the use of antihypertensives
* History of reported or recorded hypoglycemia (plasma glucose less than 70 mg/dl)
* Pregnancy
* Breast-feeding
* Use of hormone replacement therapy
* The use of contraceptive therapy
* Use of any medication other than multivitamin
* Hematocrit \<35%
* Cardiovascular disease such as history of myocardial infarction, presence of angina pectoris, significant arrhythmia, congestive heart failure(LV hypertrophy acceptable), deep vein thrombosis, pulmonary embolism, second or third degree heart block, mitral valve stenosis, aortic stenosis or hypertrophic cardiomyopathy
* Asthma
* History of angioedema
* History of cough or other side effect during ACE inhibitor use
* Impaired renal function, as defined by an eGFR\<60ml/min/1.73M2
* Clinically significant gastrointestinal impairment that could interfere with drug absorption
* Impaired hepatic function (aspartate amino transaminase\[AST\] and/or alanine amino transferase \[ALT\]\>2 x upper limit of normal range
* History of alcohol or drug abuse
* Treatment with any investigational drug in the 1 month preceding the study
* Mental conditions rendering the subject unable to understand the nature, scope and possible consequences of the study
* Inability to comply with the protocol, e.g., uncooperative attitude, inability to return to follow-up visits, and the unlikelihood of completing the study
The Lung Microbiome in Sarcoidosis

The objective of this study is to determine the presence of bacterial species, and the immunologic and molecular mechanisms of granuloma formation that might be involved in the pathogenesis of sarcoidosis. The investigators will collect peripheral blood and bronchoalveolar lavage fluid samples to isolate bacterial DNA and blood monocytes and lymphocytes. Specimens will be obtained from patients with sarcoidosis, with non-sarcoid lung disease, and healthy volunteers to directly compare the bacterial species present and the characteristics of cells thought to be involved in granuloma formation.


Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of sarcoidosis (30 subjects) or
* Clinical diagnosis of non-sarcoid interstitial lung disease (10 subjects) or
* Age-matched controls (30 subjects)
* Ability to provide informed consent

Exclusion Criteria:

* Any disease condition (such as anemia, unstable cardiac disease, etc.) that in the opinion of the subject's primary physician would put the patient at risk of harm from having 60 cc of blood drawn or for undergoing bronchoscopy for this study.
* Patients who are undergoing bronchoscopy for presumed infection.
* Pregnant women, women who may be pregnant, and women who are breastfeeding.
* Patients who have undergone lung transplantation.
* Persons who are unable or unwilling to undergo bronchoscopy, including those unable to be accompanied by a designated driver to the procedure.
* Persons who have taken antibiotics in the 90 days prior to consent.
* Known HIV, HCV, alcohol, or other substance abuse history.
Diagnosis of Prader-Willi Syndrome and Angelman Syndrome

In a retrospective study, data were assessed from cases regarding PWS/AS that underwent molecular diagnosis at the National Chen-Kung University Hospital, Tainan, Taiwan, between January 2001 and December 2014.

Prader-Willi syndrome (PWS) and Angelman syndrome (AS) are two distinct syndromes of developmental impairment that result from loss of the expression of imprinted genes on the q11-q13 region of chromosome 15 (15q11-q13). Approximately 70%--75% of individuals affected with PWS and AS have an interstitial deletion of 15q11-q13. Regarding the remaining individuals with PWS, maternal uniparental disomy is the cause in 20% of cases, imprinting errors in 3% of cases, and chromosomal translocation in approximately 1% of cases. Regarding the remaining cases of AS, paternal uniparental disomy accounts for 2% of cases and mutations in the UBE3A gene for 20% of cases.The PWS/AS critical region was examined by fluorescence in situ hybridization (FISH), methylation-specific PCR (M-PCR), and methylation-specific multiplex-ligation dependent probe amplification(MS-MLPA). In a retrospective study at the National Chen-Kung University Hospital,Tainan, Taiwan, data were reviewed from cases that were referred for molecular diagnosis between January 1, 2001, and December 31, 2014.

Eligibility Criteria:
Inclusion Criteria:

* Individual with clinical features related to Prader-Willi syndrome or Angelman syndrome;
* Fetus with suspicious deletion or duplication of chromosome 15q11.2-q13 visible by the microscope;
* Fetus whose mother or father has chromosomal abnormality involving 15q11.2-q13
* Fetus with mosaic trisomy 15

Exclusion Criteria:
Effectiveness of Two Maxillary Expanders in Improving the Transverse Skeletal and Dental Dimensions in Patients With Cleft Lip and Palate

This randomized controlled trial is designed to compare between quadlelix appliance vs hyrax expander regrading the their effectiveness in maxillary expansion in patients with cleft.


Eligibility Criteria:
Inclusion Criteria:

* Mixed dentition stage;
* Both males and females;
* Lip repair performed between 3 and 6 months of age and palate repair performed between 12 and 24 months of age;
* Presence of maxillary constriction and posterior crossbite and need for maxillary expansion previous to the secondary bone graft;
* Permanent first maxillary molars present;
* Good periodontal health;
* No previous orthodontic treatment; and

Exclusion Criteria:

* Presence of a syndrome in companion with the present cleft defect.
* Previous secondary alveolar bone grafting.
* Taking medications affecting growth.
Examining Hepatitis C Reinfection Rates in Kenya

The goal of this research project is to build upon the Testing and Linkage to Care for Injecting Drug Users (TLC-IDU) parent study and describe post-cure HCV reinfection in a population of people who inject drugs (PWIDs) in Kenya.

In addition to describing reinfection in a substance using cohort, we will identify individual predictors of HCV reinfection in Kenya, as well as identifying individual utilization intervention approaches and dosing that reduce reinfection risk and treatment cite level risk factors (frequency of visits, community vs hospital location etc.). Determining the risk factors specific to reinfection and understanding the impact of concurrent harm reduction interventions will guide service delivery and implementation of HCV elimination strategies in Kenya and throughout the region.

Eligibility Criteria:
Inclusion Criteria:

1. Live in Nairobi or coastal Mombasa (Coast Province including Malindi), Kenya;
2. Are injection drug users (IDUs) that ever injected any non-prescribed drugs; and able and willing to provide informed consent.
3. Participates are in the parent study;
4. Complete treatment protocol; and achieve a sustained virologic response (SVR).

Exclusion Criteria:

Not in the above inclusion criteria.
Pegfilgrastim PBPC Mobilization Study

This is a randomized, double-blind, multi-center study to assess the safety and effectiveness of using a single subcutaneous (under the skin) injection of pegfilgrastim or daily subcutaneous injections of Filgrastim to mobilize stem cells for autologous transplantation in patients with Hodgkin's or non-Hodgkin's lymphoma.

This is a research study for Hodgkin's Disease and Non-Hodgkin's Lymphoma (NHL) patients who will receive high-dose chemotherapy with autologous peripheral blood stem cell (PBSC or PBPC) transplant. The chemotherapy doses are high enough to severely suppress the bone marrow (where blood cells are made) and cause very low blood counts. A collection of stem cells (very young blood cells) followed by reinfusion to restore blood counts will be done to stimulate recovery of your blood counts. This procedure is called leukapheresis. Giving growth factors to patients is a method to increase the number of PBPC that can be collected during leukapheresis. This process of giving growth factors to patients is called mobilization (moving cells from the bone marrow to the peripheral blood where they can be collected). The purpose of this study is to determine if pegfilgrastim, an investigational drug, can safely and effectively mobilize stem cells. Filgrastim (also known as NEUPOGEN® or G-CSF) is approved by the FDA for stem cell mobilization. Pegfilgrastim is a modified version of Filgrastim that is longer acting.

Eligibility Criteria:
* Hodgkin's or non-Hodgkin's lymphoma patients suitable for an autologous PBPC transplant - No previous bone marrow or PBPC transplant
Patient Education in the Clinical Management of Pessary

This study is a prospective, randomized, controlled, single-blinded, multi-center clinical trial. Symptomatic patients with pelvic organ prolapse (POP) stage II, III or IV arranged to undergo pessary treatment will be randomized into either the experimental group or the control group. All patients will receive conventional verbal/paper instruction and counseling from a specialized doctor or nurse before pessary fitting, and the experimental group will receive additional patient education in the form of a re-watchable video. The video mainly includes a short introduction of pessary treatment for pelvic organ prolapse, tips and tricks for wearing and self-management of pessary, possible adverse reactions and remedy. All patients will receive regular pessary fitting and be followed up for 1 year. Self-assessment questionnaires will be used to assess the patients' willingness to pessary treatment, anxiety status, treatment satisfaction and efficacy, and to assess the patients' self-management, complications and treatment adherence. Then the differences between the two groups will be compared.


Eligibility Criteria:
Inclusion Criteria:

* Symptomatic pelvic organ prolapse of stage II\~IV
* Ability to participate in clinical trial and follow-up
* The patient and family understand the study, are willing to participate in the 1-year study, and provide written informed consent

Exclusion Criteria:

* Acute phase of infection of the internal and/or external genital tracts
* Genital fistula
* Suspected or untreated lower genital tract tumors
* Abnormally elevated intra-abdominal pressure (e.g., ascites, tumors)
* Life expectancy less than 1 year
* Cognitive or language communication disorders
* Unable to watch video (e.g., blindness)
Vaginal Fluid Wash in Pre-labour Rupture of Membranes

The investigators assess in this study the sensitivity of Urea and Creatinine and that of Nitrazine test in vaginal wash after injecting saline in the vagina of patients with pre-labour rupture of membranes

The aim of this study is to compare the accuracy of measuring the urea and creatinine level versus that of nitrazine test in vaginal wash of pre-labour rupture of membranes patients.Each patient with rupture of membranes will be assessed clinically and then if not in labour , patients will be divided into 2 groups, 5ml saline will be injected in the vagina of each patient in every group then the vaginal wash will be collected in a test tube. Urea and creatinine group, biochemical tests for urea and creatinine in mIU/ml to detect their presence in the wash will be done. In Nitrazine group wash will be assessed by nitrazine paper showing bluish discoloration in rupture membranes. Sensitivity of each test in diagnosed rupture of membranes will be assessed.Which means how many patients in each test show positive results in case of diagnosed case.

Eligibility Criteria:
Inclusion Criteria:

* Gestational age between 28 and 41 weeks
* Single intrauterine pregnancy
* History of gush of fluid
* Liquor detected on speculum examination

Exclusion Criteria:

* Vaginal bleeding
* Patients in labour
* Contaminated samples
Observational Post-Authorisation Safety Study of Asenapine (Sycrest)

The purpose of this observational study is to evaluate the use and short term safety of Asenapine (Sycrest) in real-life usage in the Mental Health Trust Setting in the United Kingdom(UK) National Health Service (NHS). The study is to be carried out independently by the Drug Safety Research Unit (DSRU) in Southampton, although it is funded by Merck, the manufacturer of Sycrest.


Eligibility Criteria:
Inclusion Criteria:

* Patients for whom a study questionnaire containing useful information has been returned

Exclusion Criteria:

* Patients who do not provide consent
* Patients within selected institutions (for example prisons)
* Patients who commenced treatment between date of market launch (to be confirmed) and study start
* Enrolled patients for whom both the baseline and 12-week questionnaires are returned blank (contain no clinical information)
* Enrolled patients for whom the psychiatrist, designated member of clinical care team, or study facilitator from the DSRU reports that the patient did not take or was never prescribed asenapine
* Enrolled patients for whom there is evidence to suggest duplication of patients
* Enrolled patients for whom informed written or verbal notification is received by DSRU indicating that they no longer wish to participate at any stage of the study